Background: Endometrial hyperplasia and carcinoma are among the most common gynecological disorders, with abnormal regulation of cell cycle proteins playing a central role in their pathogenesis. Cyclin D1, a key regulator of the G1/S phase transition, has been implicated in uncontrolled proliferation and malignant progression of endometrial tissue. This comprehensive analysis aimed to evaluate the role of Cyclin D1 dysregulation in the development and progression of endometrial hyperplasia and carcinoma.

Methods: A systematic review of relevant studies published up to [insert date] was conducted using PubMed, Scopus, Web of Science, and Google Scholar databases. Eligible articles assessing Cyclin D1 expression through immunohistochemistry, molecular profiling, or gene amplification in endometrial hyperplasia and carcinoma were included. Data were synthesized to examine expression patterns, clinicopathological correlations, and prognostic significance.

Results: Evidence consistently demonstrated overexpression of Cyclin D1 in endometrial hyperplasia with atypia and in endometrial carcinoma compared with normal endometrium, suggesting its role in early tumorigenesis. High Cyclin D1 expression was associated with increased proliferative activity, higher tumor grade, and poor prognostic markers in some studies. However, findings on its correlation with patient survival and disease recurrence remain heterogeneous. Mechanistic insights indicate that Cyclin D1 interacts with estrogen receptor signaling and other oncogenic pathways, contributing to endometrial carcinogenesis.

Conclusion: Cyclin D1 dysregulation plays a significant role in the initiation and progression of endometrial hyperplasia and carcinoma, with potential diagnostic and prognostic implications. Standardized methods for assessing Cyclin D1 expression and large-scale clinical studies are needed to clarify its utility as a biomarker and therapeutic target in endometrial pathology.

Cyclin D1, cell cycle regulation, endometrial hyperplasia

Shawana, S., Kehar, S. I., Masood, S., & Aamir, I. (2016). Immunoexpression of cyclin D1 and PTEN in various endometrial pathologies. Journal of College of Physicians and Surgeons Pakistan, 26, 277–282.

Wu, W., Slomovitz, B. M., Soliman, P. T., Schmeler, K. M., Celestino, J., et al. (2006). Correlation of cyclin D1 and cyclin D3 overexpression with the loss of PTEN expression in endometrial carcinoma. International Journal of Gynecological Cancer, 16, 1668–1672.

La Perle, K. M. (2021). Endocrine system. In Maronpot, R. R., Boorman, G. A., Gaul, B. W., et al. (Eds.), Pathology of Genetically Engineered and Other Mutant Mice (Vol. 16, pp. 355–377).

Khabaz, M. N., Abdelrahman, A. S., Butt, N. S., Al-Maghrabi, B., & Al-Maghrabi, J. (2017). Cyclin D1 is significantly associated with stage of tumor and predicts poor survival in endometrial carcinoma patients. Annals of Diagnostic Pathology, 30, 47–51.

Sudha, M., et al. (2025). [Title not provided]. Journal of Medical Sciences Research, 13(2), 90–95.

Sangwan, K., Garg, M., Pathak, N., & Bharti, L. (2020). Expression of cyclin D1 in hyperplasia and carcinoma of endometrium and its correlation with histologic grade, tumor type, and clinicopathological features. Journal of Laboratory Physicians, 12, 165–170.

Quddus, M. R., Latkovich, P., Castellani, W. J., Sung, C. J., Steinhoff, M. M., et al. (2002). Expression of cyclin D1 in normal, metaplastic, hyperplastic endometrium and endometrioid carcinoma suggests a role in endometrial carcinogenesis. Archives of Pathology & Laboratory Medicine, 126, 459–463.

Tchakarska, G., & Sola, B. (2020). The double dealing of cyclin D1. Cell Cycle, 19(2), 163–178.

Shevra, C. R., Ghosh, A., & Kumar, M. (2015). Cyclin D1 and Ki-67 expression in normal, hyperplastic and neoplastic endometrium. Journal of Postgraduate Medicine, 61, 15–20.

Özuysal, S., Öztürk, H., Bilgin, T., & Filiz, G. (2005). Expression of cyclin D1 in normal, hyperplastic and neoplastic endometrium and its correlation with Ki-67 and clinicopathological variables. Archives of Gynecology and Obstetrics, 271, 123–126.

Brucka, A., Bartczak, P., Ratyńska, M., & Sporny, S. (2009). Immunohistochemical pattern of protein P21, cyclin D1 and cyclin E in endometrial hyperplasia. Polish Journal of Pathology, 60, 19–25.

Choudhury, M., & Bansal, S. (2007). Expression of cyclin D1 in endometrial hyperplasia and endometrial carcinoma. Indian Journal of Pathology and Microbiology, 50, 708–710.

Nishimura, Y., Watanabe, J., Jobo, T., Kato, N., Fujisawa, T., et al. (2004). Cyclin D1 expression in endometrioid-type endometrial adenocarcinoma is correlated with histological grade and proliferative activity, but not with prognosis. Anticancer Research, 24, 2185–2192.

Moreno-Bueno, G., Rodríguez-Perales, S., Sánchez-Estévez, C., Marcos, R., Hardisson, D., et al. (2004). Molecular alterations associated with cyclin D1 overexpression in endometrial cancer. International Journal of Cancer, 110, 194–200.

Nan, F., Lü, Q., Zhou, J., Cheng, L., Popov, V. M., et al. (2009). Altered expression of DACH1 and cyclin D1 in endometrial cancer. Cancer Biology & Therapy, 8, 1534–1539.

Cao, Q. J., Einstein, M. H., Anderson, P. S., Runowicz, C. D., Balan, R., et al. (2002). Expression of COX-2, Ki-67, cyclin D1, and P21 in endometrial endometrioid carcinomas. International Journal of Gynecological Pathology, 21, 147–154.

Liang, S., Mu, K., Wang, Y., Zhou, Z., Zhang, J., et al. (2013). Cyclin D1, a prominent prognostic marker for endometrial diseases. Diagnostic Pathology, 8, 138.

Sangwan, K., Garg, M., Pathak, N., & Bharti, L. (2020). Expression of cyclin D1 in hyperplasia and carcinoma of endometrium and its correlation with histologic grade, tumor type, and clinicopathological features. Journal of Laboratory Physicians, 12, 165–170. [Duplicate of #6]

Szymański, M., Jerka, D., Bonowicz, K., Antosik, P., & Gagat, M. (Year not fully given). Assessment of Cyclin D1 Expression: Prognostic Value and Functional In [Incomplete reference].